Evidence supporting the use of: Cannabidiolic acid
For the health condition: Seizures

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabidiolic acid (CBDA) is the precursor to cannabidiol (CBD), a well-studied phytocannabinoid derived from Cannabis sativa. While CBD has robust clinical evidence supporting its use in certain seizure disorders, such as Dravet syndrome and Lennox-Gastaut syndrome, CBDA itself has far less direct scientific validation. Preclinical studies in animal models suggest that CBDA may possess anticonvulsant properties, possibly via modulation of serotonin receptors and enhancement of endocannabinoid signaling. For example, some rodent studies have demonstrated that CBDA can reduce seizure severity or frequency, but these findings have not been widely replicated or tested in humans. Currently, there are no large-scale clinical trials or regulatory approvals for the use of CBDA in treating seizures in humans. Most of the existing scientific literature focuses on CBD, not CBDA, and the conversion of CBDA to CBD (via decarboxylation) is typically required to achieve the well-documented anticonvulsant effects. Therefore, while there is a mechanistic rationale and preliminary animal data suggesting potential benefit, the evidence is limited and does not approach the level of support seen for CBD itself. Use of CBDA for seizures is considered experimental, and further research is needed to establish its efficacy and safety in humans.

More about Cannabidiolic acid
More about Seizures

Other health conditions supported by Cannabidiolic acid

Epilepsy
Inflammation
Pain (general remedies for)
Seizures

Products containing Cannabidiolic acid

We currently have no products on Caring Sunshine that contain this ingredient.